Page 66 - 4PDF Alin Dexametasona

DEXAMETASONA EN DERMATOLOGÍA

Referencias

1. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorti-
coids—new mechanisms for old drugs. N Engl J Med 2005; 353:
1711–1723.
2. Jackson, S., Gilchrist, H. y Nesbitt, L.T., “Update on the dermato-
logic use of systemic glucocorticosteroids”, Dermatol Ther, 2007,
20: 187-205.
3. Williams, L.C. y Nesbitt, L.T., Jr., “Update on systemic glucocor-
ticosteroids in dermatology”, Dermatol Clin, 2001, 19: 63-77.
4. Sinha A, Bagga A. Pulse Steroid Therapy. Indian Journal of Pedia-
trics. 2008; 75:1057-1066.
5. Arth G, Johnston D, Fried J, et al. 16-Methylated Steroids: I. 16-Al-
pha Methylated Analogs of Cortisone; A New Group of Anti-In-
flammatory Steroids. J Am Chem Soc. 1958; 80:3160.
6. Kanof N, Blau S. Dexamethasone in Dermatology. Arch Derma-
tol.1959;80:112-115
7. Schimmer BP, Parker KL. Adrenocorticotropic hormones; adre-
nocortical steroids and their synthetic analogs; inhibitors of the
synthesis and actions of adrenocortical hormones. In Brunton LL,
Lazo JS, Parker KL, eds. Goodman & Gilman’s The Pharmacological
Basis of Therapeutics, 11th ed. New York: McGraw-Hill Professio-
nal, 2006; 1587-1612.
8. Buttgereit F, Saag K, Cutolo M, et al. The molecular basis for the
effectiveness, toxicity, and resistance to glucocorticoids: focus on
the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;
34; 14-21.
9. Cardozo A, Bortolini F, Stefani M, et al. Systemic corticoids: A
review. Med Cutan Iber Lat Am. 2007; 35(1):35-50.
10. Van der Meer J, Schuttelaar M, Toth G. Successful dexametha-
sone pulse therapy in a toxic epidermal necrolysis (TEN) patient
featuring recurrent TEN to oxazepam. Clinical and Experimental
Dermatoloy 2001; 26:654-656.
11. Tòth G, Van de Meer J, Jonkman M. Dexamethasone pulse therapy
in pemphigus. JEADV. 2002; 16:607-611.
12. Mittal R, Sudha R, Murugan S, et al. Pulse therapy in dermatology.
Sri Ramachandra Journal of Medicine. 2007; 1(2):44-46.

65